Abstract:Summary In traditional phase I and II clinical trial designs, toxicity and efficacy are often modelled as binary outcomes. Such methods ignore information on when the outcome event occurs, such as experiencing toxicity or achieving cure or remission. They also have difficulty accommodating a high accrual rate under which toxicity and efficacy outcomes cannot be observed in a timely manner, and thus delay treatment assignment. To address these issues, we propose a Bayesian adaptive phase I–II design that jointly models toxicity and efficacy as time-to-event outcomes. At each decision-making time, patients who have not experienced toxicity or efficacy are naturally censored. We apply the marginal cure rate model to account explicitly for those patients who are insusceptible to efficacy owing to drug resistance. The correlation between the bivariate time-to-toxicity and time-to-efficacy outcomes is properly adjusted through the Clayton model. After screening out the excessively toxic or futile doses, we adaptively assign each new patient to the most appropriate dose on the basis of the ratio of the areas under the predicted survival curves corresponding to toxicity and efficacy. We conducted extensive simulation studies to examine the operating characteristics of the method proposed, and we illustrate the application of the method in a clinical trial in prostate cancer. Our design selects the target dose with a high probability, treats most patients at the desirable dose and potentially shortens the duration of a trial.

Two-phase designs with failure time processes subject to nonsusceptibility

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Efficient designs and analysis of two-phase studies with longitudinal binary data

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Alternative Designs of Phase II Trials Considering Response and Toxicity

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

A New Adaptive Design Based on Simon's Two-Stage Optimal Design for Phase II Clinical Trials.

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

Optimal Two-stage Designs with Consideration of Response and Safety and Their Correlation

Enhancing the flexibility and power of adaptive seamless phase 2/3 design with copula modeling between short-term and long-term endpoints

On Construction of Single-Arm Two-Stage Designs with Consideration of Both Response and Toxicity

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Efficient semiparametric inference for two-phase studies with outcome and covariate measurement errors